Robert B Colvin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4546851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques. American Journal of Transplantation, 2022, 22, 46-57.	4.7	64
2	Deep learning identified pathological abnormalities predictive of graft loss in kidney transplant biopsies. Kidney International, 2022, 101, 288-298.	5.2	28
3	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrology Dialysis Transplantation, 2022, 37, 507-514.	0.7	10
4	Novel intragraft regulatory lymphoid structures in kidney allograft tolerance. American Journal of Transplantation, 2022, 22, 705-716.	4.7	10
5	Kidney xenotransplantation in a brainâ€dead donor: Glass halfâ€full or halfâ€empty?. American Journal of Transplantation, 2022, , .	4.7	6
6	Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 857-873.	5.6	19
7	Prediction is hard, especially regarding the future a. American Journal of Transplantation, 2021, 21, 1357-1358.	4.7	0
8	Cutaneous leukocyte lineages in tolerant large animal and immunosuppressed clinical vascularized composite allograft recipients. American Journal of Transplantation, 2021, 21, 582-592.	4.7	4
9	Genome-wide profiling of BK polyomavirus integration in bladder cancer of kidney transplant recipients reveals mechanisms of the integration at the nucleotide level. Oncogene, 2021, 40, 46-54.	5.9	8
10	Local FK506 implants in non-human primates to prevent early acute rejection in vascularized composite allografts. Annals of Translational Medicine, 2021, 9, 1070-1070.	1.7	2
11	Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical Cancer Research, 2021, 27, 5353-5364.	7.0	13
12	Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. Journal of Clinical Investigation, 2021, 131, .	8.2	33
13	Plasmacytoid Dendritic Cell–driven Induction of Treg Is Strain Specific and Correlates With Spontaneous Acceptance of Kidney Allografts. Transplantation, 2020, 104, 39-53.	1.0	13
14	Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. Transplantation Proceedings, 2020, 52, 2720-2725.	0.6	6
15	Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing. Oncogene, 2020, 39, 5734-5742.	5.9	17
16	Case 34-2020: A 74-Year-Old Man with Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, 1768-1778.	27.0	3
17	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nature Communications, 2020, 11, 6319.	12.8	203
18	Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation–Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. American Journal of Transplantation, 2020, 20, 2305-2317.	4.7	119

#	Article	IF	CITATIONS
19	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	4.7	437
20	Toward Development of the Delayed Tolerance Induction Protocol for Vascularized Composite Allografts in Nonhuman Primates. Plastic and Reconstructive Surgery, 2020, 145, 757e-768e.	1.4	13
21	Genome-wide non-HLA donor-recipient genetic differences influence renal allograft survival via early allograft fibrosis. Kidney International, 2020, 98, 758-768.	5.2	25
22	Kidney-induced systemic tolerance of heart allografts in mice. JCI Insight, 2020, 5, .	5.0	10
23	A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal of the American Society of Nephrology: JASN, 2019, 30, 1481-1494.	6.1	67
24	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. American Journal of Transplantation, 2019, 19, 2876-2888.	4.7	95
25	Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1â€year Phase 1/2 clinical trial. Journal of Inherited Metabolic Disease, 2019, 42, 534-544.	3.6	86
26	Graft vasculopathy of vascularized composite allografts in humans: a literature review and retrospective study. Transplant International, 2019, 32, 831-838.	1.6	23
27	Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genetics in Medicine, 2019, 21, 1987-1997.	2.4	66
28	Pathology of Kidney Transplantation. , 2019, , 379-417.		0
29	Long-term Kinetics of Intragraft Gene Signatures in Renal Allograft Tolerance Induced by Transient Mixed Chimerism. Transplantation, 2019, 103, e334-e344.	1.0	15
30	The pathology of solid organ xenotransplantation. Current Opinion in Organ Transplantation, 2019, 24, 535-542.	1.6	12
31	Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight, 2019, 4, .	5.0	26
32	Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney International, 2018, 93, 789-796.	5.2	532
33	Penis Transplantation. Annals of Surgery, 2018, 267, 983-988.	4.2	68
34	Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet Journal of Rare Diseases, 2018, 13, 68.	2.7	23
35	Both platelets and fibrin deposition are increased in the glomeruli of mice after treatment with Shiga toxin-2. Kidney International, 2017, 92, 1556-1557.	5.2	2
36	Hydroxyurea for Treatment of Nephrotic Syndrome AssociatedÂWith Polycythemia Vera. American Journal of Kidney Diseases, 2016, 68, 465-468.	1.9	2

#	Article	IF	CITATIONS
37	Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients WithÂHepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting AntiviralÂTherapy. Kidney International Reports, 2016, 1, 135-143.	0.8	26
38	Haptoglobin or Hemopexin Therapy Prevents Acute Adverse Effects of Resuscitation After Prolonged Storage of Red Cells. Circulation, 2016, 134, 945-960.	1.6	61
39	Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet, The, 2016, 388, 983-993.	13.7	148
40	Systematic pathological component scores for skin-containing vascularized composite allografts. Vascularized Composite Allotransplantation, 2016, 3, 62-74.	0.5	8
41	Glomerular disease with idiopathic linear immunoglobulin deposition: a rose by any other name would be atypical. Kidney International, 2016, 89, 750-752.	5.2	16
42	Immunomodulatory Strategies Directed Toward Tolerance of Vascularized Composite Allografts. Transplantation, 2015, 99, 1590-1597.	1.0	9
43	3-dimensional digital reconstruction of the murine coronary system for the evaluation of chronic allograft vasculopathy. Diagnostic Pathology, 2015, 10, 16.	2.0	17
44	Pathology of Kidney Transplantation. , 2014, , 377-410.		3
45	Granulomatous Interstitial Nephritis as a Manifestation of Crohn Disease. Archives of Pathology and Laboratory Medicine, 2014, 138, 125-127.	2.5	23
46	Allograft Rejection. , 2014, , 197-216.		0
47	Pros and cons for C4d as a biomarker. Kidney International, 2012, 81, 628-639.	5.2	170
48	Diagnostic challenges in chronic antibody-mediated rejection. Nature Reviews Nephrology, 2012, 8, 255-257.	9.6	48
49	Chronic alloantibody mediated rejection. Seminars in Immunology, 2012, 24, 115-121.	5.6	47
50	Role of complement and NK cells in antibody mediated rejection. Human Immunology, 2012, 73, 1226-1232.	2.4	60
51	Early Acceptance of Renal Allografts in Mice Is Dependent on Foxp3+ Cells. American Journal of Pathology, 2011, 178, 1635-1645.	3.8	82
52	The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis. Journal of Autoimmunity, 2011, 37, 48-57.	6.5	22
53	Coronary Artery Disease From Isolated Non-H2-Determined Incompatibilities in Transplanted Mouse Hearts. Transplantation, 2011, 91, 847-852.	1.0	15
54	Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney International, 2011, 80, 879-885.	5.2	130

#	Article	IF	CITATIONS
55	Contributions of Direct and Indirect Alloresponses to Chronic Rejection of Kidney Allografts in Nonhuman Primates. Journal of Immunology, 2011, 187, 4589-4597.	0.8	14
56	The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting. Blood, 2011, 118, 1037-1037.	1.4	0
57	Chronic Humoral Rejection of Human Kidney Allografts Associates With Broad Autoantibody Responses. Transplantation, 2010, 89, 1239-1246.	1.0	81
58	Suppressive Regulatory T Cell Activity Is Potentiated by Glycogen Synthase Kinase 3β Inhibition. Journal of Biological Chemistry, 2010, 285, 32852-32859.	3.4	47
59	Emerging role of B cells in chronic allograft dysfunction. Kidney International, 2010, 78, S13-S17.	5.2	32
60	Regulatory, Effector, and Cytotoxic T Cell Profiles in Long-Term Kidney Transplant Patients. Journal of the American Society of Nephrology: JASN, 2009, 20, 1113-1122.	6.1	59
61	Kidney Transplantation: Mechanisms of Rejection and Acceptance. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 189-220.	22.4	182
62	Pathology of Chronic Humoral Rejection. Contributions To Nephrology, 2008, 162, 75-86.	1.1	45
63	Spontaneous Renal Allograft Acceptance Associated with "Regulatory―Dendritic Cells and IDO. Journal of Immunology, 2008, 180, 3103-3112.	0.8	75
64	Pathology of Kidney Transplantation. , 2008, , 383-415.		3
65	Antibody-Mediated Renal Allograft Rejection: Diagnosis and Pathogenesis. Journal of the American Society of Nephrology: JASN, 2007, 18, 1046-1056.	6.1	477
66	CADI, Canti, Cavi 1. Transplantation, 2007, 83, 677-678.	1.0	4
67	Renal transplant pathology: An update. Current Diagnostic Pathology, 2007, 13, 15-24.	0.4	4
68	Chronic allograft nephropathy. Current Opinion in Nephrology and Hypertension, 2005, 14, 229-234.	2.0	107
69	Antibody-mediated organ-allograft rejection. Nature Reviews Immunology, 2005, 5, 807-817.	22.7	434
70	NK Cells Can Trigger Allograft Vasculopathy: The Role of Hybrid Resistance in Solid Organ Allografts. Journal of Immunology, 2005, 175, 3424-3430.	0.8	158
71	C4d deposition in allografts: current concepts and interpretation. Transplantation Reviews, 2005, 19, 65-77.	2.9	37
72	Biomarkers and Surrogate Endpoints in Renal Transplantation: Present Status and Considerations for Clinical Trial Design. American Journal of Transplantation, 2004, 4, 451-457.	4.7	64

#	Article	IF	CITATIONS
73	Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates1. Transplantation, 2004, 77, 460-462.	1.0	103
74	Antibody-Mediated Rejection Criteria - an Addition to the Banff '97 Classification of Renal Allograft Rejection. American Journal of Transplantation, 2003, 3, 708-714.	4.7	960
75	Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study. American Journal of Transplantation, 2003, 3, 722-730.	4.7	360
76	Chronic Allograft Nephropathy. New England Journal of Medicine, 2003, 349, 2288-2290.	27.0	94
77	Acute Humoral Rejection in Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2002, 13, 779-787.	6.1	453
78	ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1. Transplantation, 2001, 71, 652-658.	1.0	311
79	Tolerance, Mixed Chimerism, and Chronic Transplant Arteriopathy. Journal of Immunology, 2001, 167, 5731-5740.	0.8	76
80	Chronic Humoral Rejection. Journal of the American Society of Nephrology: JASN, 2001, 12, 574-582.	6.1	430
81	The Banff 97 working classification of renal allograft pathology. Kidney International, 1999, 55, 713-723.	5.2	2,817
82	Complement Activation in Acute Humoral Renal Allograft Rejection. Journal of the American Society of Nephrology: JASN, 1999, 10, 2208-2214.	6.1	469
83	Xenotransplantation—caution, but no moratorium. Nature Medicine, 1998, 4, 372-372.	30.7	12
84	PLASMA EXCHANGE AND TACROLIMUS-MYCOPHENOLATE RESCUE FOR ACUTE HUMORAL REJECTION IN KIDNEY TRANSPLANTATION1. Transplantation, 1998, 66, 1460-1464.	1.0	190
85	ALLOANTIBODY- AND T CELL-MEDIATED IMMUNITY IN THE PATHOGENESIS OF TRANSPLANT ARTERIOSCLEROSIS. Transplantation, 1997, 64, 1531-1536.	1.0	142
86	Xenotransplantation of pig kidneys to nonhuman primates: I. Development of the model. Xenotransplantation, 1995, 2, 264-270.	2.8	76
87	Expression of fibronectin isoforms in rat cornea after an epithelial-scrape wound. Current Eye Research, 1994, 13, 325-330.	1.5	10
88	CORONARY ATHEROSCLEROSIS IN TRANSPLANTED MOUSE HEARTS. Transplantation, 1994, 57, 1367-1371.	1.0	71
89	International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney International, 1993, 44, 411-422.	5.2	1,305
90	DNA flow cytometry of epithelioid sarcoma. Cancer, 1992, 70, 2823-2826.	4.1	16

6

#	Article	IF	CITATIONS
91	Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumorâ€infiltrating lymphocytes. Cancer, 1992, 69, 1165-1173.	4.1	62
92	Dietary fish oil reduces progression of established renal disease in (NZB × NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis and Rheumatism, 1986, 29, 539-546.	6.7	145
93	Fibronectin in developing rabbit cornea. Current Eye Research, 1984, 3, 489-499.	1.5	28
94	Immunopathologic Characterization of a Monoclonal Antibody that Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types. American Journal of Clinical Pathology, 1983, 79, 98-104.	0.7	338
95	Reaction of Normal Human Lymphocytes and Chronic Lymphocytic Leukemia Cells With an Antithymocyte Antiserum. Blood, 1973, 41, 417-423.	1.4	40
96	The Surgical Management of Renal Cell Carcinoma. Journal of Urology, 1972, 107, 705-710.	0.4	183
97	Extension of Renal Cell Carcinoma into the Vena Cava: The Rationale for Aggressive Surgical Management. Journal of Urology, 1972, 107, 711-716.	0.4	322
98	Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases. Cancer, 1971, 28, 1165-1177.	4.1	973
99	Major complications ??? pathology of chronic rejection. , 0, , 38-45.		2